All PLWH who are coinfected with HCV should be offered curative HCV treatment. Nonadherence to ART or a lack of HIV suppression should not affect candidacy for treatment of HCV.
Managing people living with both HIV and HCV and polypharmacy can be difficult. How do you analyze which HCV regimen to use and identify relevant drug interactions?
Treatment of HCV/HIV coinfection requires continued awareness of and attention to the complex drug–drug interactions that can occur, especially when using pharmacologically boosted ARVs and nonnucleoside reverse transcriptase inhibitors. Here’s my take on how to approach drug–drug interactions using patient cases.
Listen as expert faculty answer clinicians’ questions about specific challenges in managing HCV/HIV coinfection, including how to apply guideline-based strategies, avoid common DAA and ART interactions, incorporate recent therapy approvals, and more.
Use this Interactive Decision Support Tool to get guideline-based treatment recommendations from Susanna Naggie, MD, MHS, and Mark S. Sulkowski, MD, for your patients with HCV/HIV coinfection.
Learn expert insights on choosing DAAs and ART for patients with HCV/HIV coinfection in this succinct and focused module.
Gain expert perspective on selecting optimal DAA and ARV combinations for patients with HCV/HIV coinfection in this downloadable slideset.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.